GITAM (Deemed to be University), Visakhapatnam, is developing a blood test for early detection of triple-negative breast cancer (TNBC) under an ICMR-funded project.
The three-year project, worth over ₹2 crore, was sanctioned under ICMR's Follow-on Nischayak Anveshan Extramural Grants programme.
It looks for microRNA biomarkers inside exosomes in blood serum, using sequencing, digital PCR and a machine-learning model.
The goal is a kit-based test; the work is still at the research stage.
Tumour cells release exosomes — nanosized membrane vesicles carrying proteins and nucleic acids — into blood. MicroRNAs inside them are small non-coding RNAs that regulate genes, and their pattern can flag cancer early without a tissue biopsy.
Simple Analogy: Reading the tumour's mail instead of breaking into its house.
| Subtype | Receptors present | Targeted treatment |
|---|---|---|
| Hormone-receptor positive | Oestrogen and/or progesterone receptors | Hormone therapy (e.g., tamoxifen) |
| HER2-positive | Excess HER2 protein | Anti-HER2 drugs (e.g., trastuzumab) |
| Triple-negative (TNBC) | None of ER, PR or excess HER2 | No receptor-targeted therapy; mainly chemotherapy |
Apex body for formulating, coordinating and promoting biomedical research; founded in 1911 as the Indian Research Fund Association, renamed ICMR in 1949; under the Department of Health Research, Ministry of Health and Family Welfare
Extramural funding for Indian scientists working outside ICMR's own institutes; the Follow-on stream continues earlier ICMR-funded work
Host institution of the project
GS Paper III > Science and Technology > Biotechnology; GS Paper II > Health
General Science > Biology > Human diseases
Breast cancer that lacks oestrogen and progesterone receptors and does not overexpress HER2.
Nanosized membrane-bound vesicle released by cells, carrying proteins and nucleic acids between cells.
PCR that splits a sample into thousands of separate reactions to count target nucleic acid molecules directly.